Mark A. Nagy
Ophthalmology
45 Johnstone Dr
Apt 301
San Francisco, CA 94131
Apt 301
San Francisco, CA 94131
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Discovery of Potential First-in-Class Dual Ligand-Directed Degrader and Antagonist of the Androgen Receptor: BMS-986365.
Journal: Journal of medicinal chemistry
Published: July 10, 2026
Discovery of the c-Jun N-Terminal Kinase Inhibitor CC-90001.
Journal: Journal of medicinal chemistry
Published: December 13, 2021
CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia.
Journal: Journal of medicinal chemistry
Published: February 16, 2021
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.
Journal: Journal of medicinal chemistry
Published: March 05, 2020
Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy.
Journal: Journal of medicinal chemistry
Published: April 19, 2019
The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen.
Journal: Journal of medicinal chemistry
Published: October 10, 2017
Showing 1-6 of 6
Last Updated: 09/26/2026